Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying abo...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。